BUND FINANCE › Stocks › SNY
Sanofi (SNY)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +9.96% above its 50-day average.
- It is +6.20% above its 200-day average (long-term uptrend).
- It sits at 70% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | EUR 39.2B | EUR 40.6B | EUR 41.6B | EUR 44.3B | EUR 46.7B |
| Net income | EUR 6.2B | EUR 8.4B | EUR 5.4B | EUR 5.6B | EUR 7.8B |
| EPS (diluted) | 2.49 | 3.18 | 2.15 | 2.19 | 3.20 |
| Gross margin | 68.7% | 70.7% | 69.7% | 70.2% | 72.1% |
| Operating margin | 20.7% | 25.1% | 16.7% | 16.4% | 20.5% |
| Net margin | 15.9% | 20.6% | 13.0% | 12.6% | 16.7% |
| Free cash flow | EUR 8.5B | EUR 8.4B | EUR 7.4B | EUR 5.9B | EUR 7.2B |
| Total debt | EUR 22.4B | EUR 21.2B | EUR 18.7B | EUR 17.9B | EUR 20.3B |
| Cash | EUR 10.1B | EUR 12.7B | EUR 8.7B | EUR 7.4B | EUR 7.7B |
Compound annual growth: revenue 4.5% · net income 5.9% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | — | 17.4x | 27.1x |
| EV / EBITDA | — | 10.2x | 16.5x |
| Operating margin | 16.3% | — | 3.6% |
| Net margin | 8.2% | — | -0.0% |
| Debt / equity | 0.78 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation. The company reports in another currency: amounts are shown in that currency.
About Sanofi
Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a po…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice